There is provided a process for producing a medical, material that retains the properties which are inherent in a polyanionic polysaccharide being a raw material, that has a high level of safety because there is no need to use a chemical crosslinking agent, and that has moderate strength and flexibility. The present invention is a process for producing a medical material, the process including a step of dispersing a powder or a granular product of a first polyanionic polysaccharide, the first polyanionic polysaccharide water-insolubilized with a treatment liquid containing a first acid anhydride, in an aqueous solution of a water-soluble salt of a second polyanionic polysaccharide, thereby obtaining a dispersion liquid, a step of drying the dispersion liquid obtained, thereby obtaining a dried film, and a step of water-insolubilizing the dried film obtained with a treatment liquid containing a second acid anhydride, thereby obtaining the medical material.

Provided are compositions that can be employed for generating microporous gel systems. In some embodiments, the compositions include at least one sub-population of soft hydrogel microparticles with a Youngs modulus of less than 50 kPa and at least one sub-population of stiff hydrogel microparticles with a Young's modulus of greater than 90 kPa. Also provided are methods for generating the compositions, methods for treating bone and/or cartilage defects in subject using the disclosed compositions, methods for treating osteoarthritis using the disclosed compositions, and methods for providing orthopedic implants to subjects.

Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided.

Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.

The present invention provides a valve material having synergistic anti-coagulation and anti-calcification functions and a preparation method therefor. The preparation method comprises the following steps: performing glutaraldehyde cross-linking treatment on an animal-derived biological valve material; immersing the treated valve material in a blocking solution containing an amine compound for 0.5-6 h, thereby blocking the remaining aldehyde groups after glutaraldehyde cross-linking; then placing the valve material into a reaction solution containing an anticoagulant and a cross-linking agent, and performing cross-linking treatment for 6-24 h at 4° C.-37° C.; and finally washing and obtaining the valve material, and storing the valve material in a mixed solvent of glutaraldehyde or isopropyl alcohol/glycerol. The method can effectively solve the problem of calcification and thrombosis caused by residual aldehyde groups in a valve material prepared by the existing method. The valve material prepared by the present method can be used as a valve material required for aortic valve, pulmonary valve, venous valve, mitral valve and tricuspid valve replacement.

A medical treatment system for determining administration of medications to a patient is disclosed. The system uses a plurality of sensors to perform a first set of physiologic measurements in a right side of the heart and a second set of physiologic measurements in a left side of the heart. The system also includes a receiver configured to receive measurement data regarding the first and second sets of physiologic measurements and output to a display device the received measurement data.

The present invention provides an artificial skin and a preparation method thereof. The present invention takes the xenogeneic acellular dermal matrix particles as main materials, and obtains the dermis layer by three-dimensional printing technologies, and then obtains the artificial skin by combining the epidermis layer with the dermis layer. The dermis layer of artificial skin in present invention has three-dimensional porous structure, which retains main components of natural dermal matrix in composition, and imitates distributed structure at fiber bundle diameter and pore size of natural dermal matrix in structure. This kind of novel biomimetic dermal scaffolds have obvious advantages in inducing migration and regeneration of skin cells, accelerating vascularization, promoting wound healing and improving healing quality. The dermis layer of artificial skin in present invention is obtained by three-dimensional printing technologies, which has precise and controllable structure, simple preparation method and high products qualification rate.

The present patent document describes methods for enhancing the aesthetic appearance of a human face by injecting soft tissue filler material in the temporal region. The soft tissue filler material is injected into a subdermal plane; preferably from an injection site about 1 cm anterior to the apex of the tragus. A single injection may be performed on either side of the face.

According to the invention there is provided inter alia a process for the manufacture of a solid object having a surface comprising a layered coating of cationic and anionic polymer wherein the outer coating layer comprises an anticoagulant entity, comprising the steps of: i) treating a surface of the solid object with a cationic polymer; ii) treating the surface with an anionic polymer; iii) optionally repeating steps i) and ii) one or more times; iv) treating the surface with a cationic polymer; and v) treating the outermost layer of cationic polymer with an anticoagulant entity, thereby to covalently attach the anticoagulant entity to the outermost layer of cationic polymer; wherein, the anionic polymer is characterized by having (a) a total molecular weight of 650 kDa-10,000 kDa; and (b) a solution charge density of >4 μeq/g; and wherein, step ii) is carried out at a salt concentration of 0.25 M-5.0 M.

The present disclosure provides methods of improving structure of a face in a patient, more particularly by classifying the facial shape in order to allow the design of a specific treatment plan directed to each type of face shape.